Market Overview
Size, use case, and demand mix
- Brevintel analysis values the rapid influenza diagnostic tests market at USD 1.5 billion in 2025 ($1.5B), expanding from USD 1.6 billion in 2026 to USD 2.5 billion in 2035 ($2.5B) at a 4.9% CAGR.
- A more granular 2025 reading of USD 1,484.69 million sits under the USD 1.5 billion headline after approximately 9.8% historical expansion between 2022 and 2025.
- RIDTs are immunoassays that detect influenza A and B viral nucleoprotein antigens in respiratory specimens, typically producing qualitative results in less than 15 minutes.
- Abbott led with over 20% market share in 2025; Abbott, Quidel Corporation, Roche, Thermo Fisher Scientific, and Becton Dickinson and Company (BD) collectively held 65%.
- U.S. clinical laboratories tested 3,978,954 respiratory specimens during the 2024–25 season, and 489,579 were positive.
- Positivity reached its highest weekly peak in nine seasons during the week ending February 1, 2025, showing why seasonal surges still support rapid-test purchasing as longer-term growth normalizes.
- Immunochromatographic and lateral-flow formats remain central because they combine short turnaround with decentralized deployment, while digital immunoassays, multiplex panels, and point-of-care nucleic-acid amplification tests widen performance options.
- Demand is increasingly tied to whether a result changes an immediate triage, isolation, treatment, or referral decision rather than to exceptional pandemic-era testing volumes.
Regulatory floor and clinical placement
- In the United States, RIDTs are Class II devices subject to special controls, including minimum sensitivity and specificity requirements against RT-PCR for influenza A and B detection.
- FDA special controls require antigen RIDTs to meet performance thresholds of at least 80% sensitivity and 95% specificity against RT-PCR.
- WHO 2024 clinical practice guidelines support digital immunoassays or nucleic-acid amplification tests in defined settings, particularly where patients have elevated risk of severe disease.
- WHO Essential Diagnostics List SAGE IVD Recommendation No. 168 supports influenza A and B point-of-care testing across primary care, district hospitals, and higher-level facilities.
- CDC guidance notes that rapid tests can support clinical decision-making, while negative antigen results should be interpreted in the context of influenza activity because false-negative results can occur.
- That distinction favors tests placed near triage, outpatient, emergency, and community-care settings rather than assays that depend only on centralized processing.
- Suppliers that combine dependable seasonal availability with performance suited to frontline decision-making should be better placed than suppliers competing only on low unit price.
- FDA influenza diagnostic test information for in vitro diagnostics was updated July 22, 2024, reinforcing the importance of documented assay quality in U.S. procurement.
Market Dynamics
Drivers
- Influenza burden creates episodic demand concentrated around short seasonal windows, making turnaround time commercially important for triage, infection-control, and treatment decisions.
- During the 2024–25 U.S. season, influenza A represented 88.8% of positive clinical-laboratory tests, and influenza A positivity reached 30.4% in late January 2025.
- This seasonality favors suppliers able to maintain inventory reliability and support decentralized testing sites even when weekly intensity recedes.
- Digital immunoassays and point-of-care nucleic-acid amplification tests address a key limitation of conventional visual-read antigen testing: variable performance and interpretation at the point of use.
- WHO conditionally recommends digital immunoassays or nucleic-acid amplification tests for suspected non-severe influenza and supports point-of-care versions for patients at high risk of severe disease.
- U.S. emergency-department influenza testing rose from 2.5% of visits in 2013 to 10.9% in 2022, reaching an estimated 16.99 million weighted visits with influenza testing.
- Earlier diagnosis matters most where clinicians must make treatment, isolation, or escalation decisions before confirmatory laboratory results become available.
- Adoption also depends on training, specimen collection, connectivity, procurement packaging, and availability during influenza peaks, not only on analytical performance.
Restraints
- Rapid testing reduces turnaround time, but it does not eliminate the need for sound specimen collection, quality assurance, and result interpretation.
- CDC guidance cautions that RIDTs have lower sensitivity than RT-PCR and that a negative result does not necessarily exclude influenza when community activity is high.
- The constraint is most material where point-of-care testing expands faster than laboratory-management capacity, particularly for digital and multiplex platforms that need operator training or documentation.
- In sites without trained staff or reliable confirmatory pathways, imperfect antigen performance can reduce confidence in routine RIDT use.
- Stringent regulatory approvals support product quality but extend development and market-entry timelines across circulating strains, specimen types, and intended-use settings.
- FDA Class II special controls requiring at least 80% sensitivity and 95% specificity against RT-PCR can reinforce established suppliers with validation resources and post-market infrastructure.
- The approval burden can also slow geographic expansion for smaller companies, particularly where products require separate evidence packages or local registration across multiple jurisdictions.
- Technology adoption will not displace conventional RIDTs uniformly: higher-performing formats gain traction where clinical risk, throughput, reimbursement, or laboratory governance justify additional system cost.
Segmentation Analysis
Product type
- Conventional RIDTs remain important because they address settings where affordability, simplicity, and rapid deployment outweigh the need for instrument-based interpretation.
- Their role is reinforced in decentralized locations that need influenza screening during seasonal peaks but may not have the throughput or capital budget for analyzers.
- Brevintel analysis of North America shows conventional RIDTs expanding from USD 387.93 million in 2025 to USD 500.42 million by 2035.
- Digital RIDTs address interpretation consistency and can be more attractive in organized care networks, emergency settings, and facilities with established quality-management processes.
- Digital RIDTs in North America increase from USD 239.50 million in 2025 to USD 323.15 million over the same period.
- The segment opportunity is linked less to replacing every conventional test and more to upgrading testing points where documentation, standardized interpretation, and clinical confidence carry higher value.
- Parallel growth reflects a segmented market in which accessibility and clinical confidence are both valuable rather than a single migration path.
- Suppliers should avoid positioning digital systems as a simple substitute for low-cost antigen formats; the commercial case is strongest where improved interpretation or performance changes the care pathway.
Technology
- Immunochromatographic and lateral-flow assays remain the core rapid-test technologies because they are aligned with the defining RIDT requirement of near-patient results in a short time frame.
- Their commercial strength lies in accessible workflows, but their performance profile requires appropriate use conditions and clinical interpretation.
- PCR and other molecular approaches serve a different portion of the diagnostic pathway, where higher analytical confidence, multiplex respiratory testing, or testing of high-risk patients is required.
- WHO guidance supports use of point-of-care nucleic-acid amplification tests and digital immunoassays in these circumstances, creating a technology ladder rather than a single-format market.
- In cost-sensitive settings, conventional antigen formats retain relevance because their workflow and infrastructure requirements are limited.
- Higher-performing digital and molecular formats are more likely to gain traction where clinical risk, throughput, reimbursement, or laboratory-governance requirements justify the additional system cost.
- Technology adoption will not displace conventional RIDTs uniformly across hospitals, diagnostic centers, and community sites.
- Multiplex respiratory panels broaden the performance and workflow options available to providers alongside antigen formats.
Sample type and end use
- Nasal swabs are well aligned with point-of-care testing because collection can be integrated into ambulatory and acute-care intake workflows.
- Sample collection remains a meaningful determinant of real-world performance, however, since poor collection can weaken the utility of an otherwise appropriate assay.
- Throat swabs and other sample types remain relevant where patient tolerance, clinical protocols, or a test's authorized instructions for use support alternative collection methods.
- Manufacturers must align packaging, instructions, and training materials with the specific specimen claims supported by their regulatory authorization.
- Diagnostic centers benefit from rapid tests when they need to manage seasonal volume efficiently while retaining access to confirmatory testing.
- Hospitals use rapid influenza testing in triage and infection-control workflows, particularly when a result can influence isolation, treatment, or admission decisions.
- CDC NCHS Data Brief No. 517, December 2024, shows influenza testing increased across all four U.S. regions and among all age groups in emergency departments.
- Research laboratories and other end users represent a distinct demand base because selection criteria may emphasize comparative performance, surveillance needs, or compatibility with broader respiratory-testing workflows.
Regional Outlook
North America
- North America represented USD 510.01 million, or 34.35%, of the global market in 2025 and is projected to reach USD 823.57 million by 2035.
- The United States accounted for USD 479.34 million of the regional total in 2025, while Canada contributed USD 30.66 million.
- The region's scale reflects established clinical testing pathways, regulatory oversight, and recurring influenza surveillance activity.
- U.S. demand is supported by a large testing base and recurring seasonal pressure, including nearly 4.0 million respiratory specimens processed by clinical laboratories during the 2024–25 influenza season.
- Emergency-department testing penetration had already increased materially over the preceding decade, supporting use across hospitals, diagnostic centers, and decentralized care sites.
- FDA performance controls raise the importance of documented assay quality in this market, alongside the July 22, 2024 influenza in vitro diagnostics update.
- North America remains the largest market, but its 4.69% forecast CAGR is below Asia Pacific's 5.86% outlook.
- The competitive center of gravity is therefore broadening even though North America retains the largest revenue base.
Europe
- Europe generated USD 414.73 million in 2025 and is projected to reach USD 660.08 million by 2035.
- Germany, the UK, France, Spain, Italy, and the Netherlands form the principal country markets within the region.
- Demand is shaped by the need to deploy tests that can function within established primary-care, hospital, and laboratory networks while meeting jurisdiction-specific product-access requirements.
- The regional opportunity is likely to favor products with clear clinical positioning rather than a single product format.
- WHO's 2024 guidance differentiates between digital immunoassays and nucleic-acid amplification tests according to disease severity and patient risk, reinforcing the value of portfolio breadth.
- Europe's projected incremental growth through 2035 is smaller than Asia Pacific's USD 289.05 million addition over the same period.
- Established networks support both conventional antigen screening and higher-confidence follow-up testing where patient risk is elevated.
- Procurement, training, and confirmatory pathways still determine whether rapid tests become embedded in routine European care.
Asia Pacific, Latin America, and Middle East and Africa
- Asia Pacific reached USD 376.97 million in 2025 and is projected to expand to USD 666.02 million by 2035.
- At a projected 5.86% CAGR, the region is expected to outpace the global 4.9% path and add USD 289.05 million in revenue between 2025 and 2035, exceeding Europe's projected incremental growth.
- The region is also the only major geography expected to record a material share gain, rising from 25.39% of global revenue in 2025 to 27.12% in 2035.
- China, Japan, India, Australia, and South Korea are the key country markets, and Asia Pacific's expected 1.73-percentage-point global share gain is significant in a market otherwise led by established regions.
- WHO support for point-of-care influenza tests across primary care, district hospitals, and higher-level facilities is relevant where access expansion and public procurement can widen use beyond specialist laboratories.
- Latin America accounted for USD 123.15 million in 2025 and is projected to reach USD 210.50 million by 2035, with Brazil, Mexico, and Argentina as the principal country markets.
- Growth in Latin America depends on whether health systems can combine access to tests with training, supply continuity, and pathways for managing negative results during elevated influenza activity.
- Conventional formats may remain attractive in Latin America where decentralization is needed but instrument infrastructure is limited, while digital or molecular systems require a clearer clinical and procurement rationale.
- The Middle East and Africa market totaled USD 59.84 million in 2025 and is expected to reach USD 95.89 million by 2035, with South Africa, Saudi Arabia, and the UAE as designated country markets.
- The region's opportunity is closely tied to surveillance capacity, public-sector procurement, and the ability of providers to embed rapid testing in defined care pathways, including follow-up testing for clinically significant negative results.
Competitive Landscape
Structure and positioning
- The RIDT market is characterized by competition across conventional antigen testing, digital interpretation, multiplex respiratory testing, and molecular diagnostic pathways.
- Product performance alone does not determine market position; regulatory clearance, distribution reach, seasonal supply reliability, and clinical-workflow compatibility are equally important.
- Abbott led with over 20% market share in 2025, and the top five players collectively held 65%.
- Abbott's rapid-test presence is most relevant where low-complexity deployment and broad access are required.
- Becton Dickinson and Company (BD) is linked to institutional diagnostic workflows and the integration of respiratory testing into clinical operations.
- Roche's strength is most applicable where hospitals and laboratories prioritize platform performance, multiplexing, and connectivity.
- FDA special controls for RIDTs require specified sensitivity and specificity thresholds versus RT-PCR, creating a meaningful compliance hurdle for new entrants.
- Smaller competitors can still compete effectively where they offer a targeted format, local distribution strength, or a commercially viable response to an underserved care setting.
Integrated producers
- Abbott
- Roche
- Thermo Fisher Scientific
- Becton Dickinson and Company (BD)
- Siemens Healthineers
- bioMérieux
- DiaSorin
Specialty suppliers
- Quidel Corporation
- 3B BlackBio
- Access Bio
- CHEMBIO
- Meridian
- SEKISUI